Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Gazprom reduced gas production by 25% in the 1st half of the year

9/28/23 GAZP

China allows pork supplies from Russia

9/28/23 RAGR

China allows pork supplies from Russia

9/28/23 GCHE

LESK reported for 6 months of 2023 by IFRS

9/28/23 LPSB

Ozon will open the country's first ПВЗ on the airport territory

9/28/23 OZON

Shareholders of Tatneft approved dividends for 6 months 2023

9/28/23 TATN

Lukoil retained the right to handle Russian oil in Bulgaria for a year

9/28/23 LKOH

Severstal may build a pelletizing complex in Cherepovets

9/28/23 CHMF

Ozon will obtain a primary listing on the Moscow Exchange

9/28/23 OZON

VSMPO-AVISMA reported for 6 months of 2023 by IFRS

9/28/23 VSMO